We examined the efficacy and safety of an all-oral interferon-free regimen of ombitasvir , an NS@A inhibitor , and paritaprevir ( ABT-@ ) , an NS@/@A protease inhibitor dosed with ritonavir ( ombitasvir plus paritaprevir plus ritonavir ) , given with or without ribavirin .